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Background: DOTAP/cholesterol-based lipoplexes are successfully used for delivery of 
plasmid DNA in vivo especially to the lungs, although low systemic stability and circulation 
have been reported. To achieve the aim of discovering the best method for systemic delivery 
of DNA to disseminated tumors we evaluated the potential of formulating DOTAP/cholesterol 
lipoplexes with a polyethylene glycol (PEG)-modified lipid, giving the benefit of the   shielding 
and stabilizing properties of PEG in the bloodstream. 
Method: A direct comparison of   properties in vitro and in vivo of 4 different DOTAP/ 
cholesterol-based lipoplexes containing 0%, 2%, 4%, and 10% PEG was performed using 
reporter gene activity and radioactive tracer lipid   markers to monitor biodistribution. 
Results: We found that 10% PEGylation of lipoplexes caused reduced retention in lung and heart 
tissues of nude mice compared to nonPEGylated lipoplexes,   however no significant delivery to 
xenograft flank tumors was observed. Although PEGylated and   nonPEGylated lipoplexes were 
delivered to cells the ability to mediate successful transfection is hampered upon PEGylation, 
presumably due to a changed uptake mechanism and intracellular processing. 
Conclusion: The eminent in vivo transfection potency of DOTAP/cholesterol-based lipoplexes 
is well established for expression in lung tumors, but it is   unsuitable for expression in non first 
pass organs such as xenograft flank tumors in mice even after addition of a PEG-lipid in the 
formulation.
Keywords: gene delivery, DOTAP, polyethylene glycol (PEG), biodistribution, lung cancer, 
xenograft tumor model
Efficient gene delivery in vivo based on nonviral methods remains a major   challenge in 
the field of gene therapy, where an overwhelming variety of polymeric and   liposomal 
compounds have been tested.1 A major obstacle has been the fact that extremely efficient 
methods involving cationic liposomes for gene delivery to cells in vitro   perform very 
poorly when tested in animals.2 Although a regime of   transfection-potent   lipoplexes 
has been established in vitro,3,4 presumably in vivo applications require   different 
physical and chemical properties and limited information about the   performance for 
in vivo delivery has emerged.
A notable exception is 1,2-dioleoyl-3-trimethylammonium-propane/cholesterol 
(DOTAP/chol)-based lipoplexes, that are potent in cellular transfection and   importantly 
facilitate systemic delivery of DNA to cells in vivo.5–8 DOTAP/chol complexed to 
  plasmid DNA encoding the tumor suppressor gene FUS1 has been used   successfully 
for the treatment of xenograft tumor model of non-small cell lung carcinoma (NSCLC)9 
and is currently being exploited in a clinical setting for the treatment of NSCLC International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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patients. When these lipoplexes are administered to end-stage 
NSCLC patients a positive response has been reported.10
DOTAP/chol-based lipoplexes show attractive   properties: 
i) Easy formulation in that preformed liposomes are simply 
mixed with plasmid DNA and spontaneously organize 
into multilaminary vesicles11 and ii) the preparation of 
these   particles for clinical use has been refined and is 
FDA approved.12 However suboptimal properties relating 
to   systemic stability have been reported when tested in 
  comparison to other formulations.2,13
To develop a strategy involving transcriptionally   targeted 
suicide gene therapy of small cell lung carcinoma (SCLC),14–16 
which at the time of diagnosis often appear disseminated to 
various extrathoracic organs,17 a systemic distribution of the 
therapeutic agent is demanded. It remains to be determined 
if DOTAP/chol is an optimal choice for this malignancy or 
whether improvements must be made for systemic stability 
and circulation.
Liposome modification by a shielding poly-ethylene-glycol 
(PEG) component in the formulation has been reported to 
enhance the systemic stability greatly.18–22 Furthermore the 
  biophysical relationship between liposome surface   concentration 
and structure of PEG has been characterized in detail.23,24 Recent 
reports about the delivery of plasmid and siRNA in vivo using 
cationic lipoplexes that also contain a PEG-lipid for improved 
efficiency19,25,26 prompted us to assess the usability of different 
degrees of PEGylation of DOTAP/chol/plasmid DNA lipo-
plexes in relation to improved   systemic circulation and stability 
while   maintaining the favorable transfection properties.
Hence, in the present study we aimed to evaluate the effect 
of increasing PEGylation of DOTAP/chol lipoplex-mediated 
gene delivery in the form of plasmid DNA and characterize 
the biophysical properties in relation to systemic stability, 
  biodistribution, and uptake mechanism. Using enhanced green 
fluorescence protein (EGFP) and firefly luciferase (LUC) reporter 
genes, endocytosis inhibitors, and labeled lipids we investigate 
the potential use for systemic tumor delivery and assess the bar-
riers operating at the level of intracellular uptake.
Material and methods
Materials
All chemicals eg, synthetic cholesterol were purchased 
from Sigma-Aldrich Inc. (Brøndby, Denmark) unless 
otherwise stated. DOTAP (N-[1-(2,3-dioleyl)propyl]-
N,N,N-  trimethylammonium chloride), DSPE-PEG2000 
(1,2-distearoyl-sn-glycero-3-  phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] and 25-NBD-cholesterol 
(25-[N-[(7-nitro-2-1,3-  benzoxadiazol-4-yl)methyl]
amino]-27-norcholesterol) were purchased from Avanti 
Polar Lipids Inc. (Alabaster, AL, USA). [1,2-3H]-Cholesteryl 
Hexadecyl Ether (3H-CHE) was   purchased from Perkin Elmer 
(Skovlunde, Denmark). High quality plasmids: pCMV-LUC 
(sequence available upon request) and   pEGFP-N1 (Clontech, 
Mountain View, CA, USA) preparations were made with the 
endo-free Giga kit from Qiagen GmbH (Hilden, Germany) 
according to the   manufacturer’s instructions. Glassware 
used for lipid work was washed and rinsed in milliQ water, 
baked at 180°C for 6 hours and dust was removed using pres-
surized air. Lipid solutions in chloroform were handled with 
gastight glass syringes (Hamilton, VWR, Herlev, Denmark) 
reserved for this purpose. Syringes were rinsed with chloro-
form and 20% ethanol in water only.
The H1299 and NCI-H69 cell lines (obtained from ATCC, 
Boras, Sweden) were cultivated in RPMI medium   supplemented 
with pen-strep and 10% fetal calf serum (  Invitrogen Inc., 
Taastrup, Denmark). Six week old male NMRI mice were 
bought from Taconic Europe (Lille Skensved, Denmark) and 
housed at Department of   Experimental Medicine, University 
of Copenhagen. All animal experiments were performed 
according to ethical guidelines and under valid license from 
the Danish Animal Experimentation Board.
Method
Preparation of DOTAP/cholesterol/ 
DSPE-PEG2000 liposomes
The protocol described by Ramesh7 for preparation of 
DOTAP/chol liposomes at the 300 µmoL scale was fol-
lowed with minor modifications. Briefly, equimolar amounts 
(150 µmoL each) of the lipids were dissolved and mixed 
in chloroform and placed in a rota-vaporator (BÜCHI 
Labortechnik AG, Flawil, Switzerland) in a 1 L round 
glass bottle. The solvent was evaporated under a nitrogen 
gas stream and the lipid film was dried by high-vacuum for 
  several hours. Hydration was done by adding 7 mL glucose 
(5%) solution resulting in a 40 mM total lipid   concentration 
and placed at 50°C for 30 minutes with repeated rotary 
movement to ensure complete hydration of the lipids and left 
overnight at room temperature. The next day the liposome 
preparation was placed in a metal basket and sonicated for 
5 minutes at 50°C using a Bransonic water bath (MT-1510, 
42 kHz, 80 W, setting “sonics”, Branson Ultrasonics, 
  Danbury, CT, USA) and then downsized using 11 passes 
in a   small-scale extruder (Avanti Polar) with polycarbonate 
nanopore filters (400 nm, 200 nm, and 100 nm, Whatman, 
Frisenette, Knebel, Denmark) at 50°C. This reagent was 
designated A-0.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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For investigations about the effect of PEGylation,   liposomes 
were prepared at a smaller scale (20 µmoL). Chloroform solu-
tions of DOTAP, cholesterol, and   eventually DSPE-PEG2000 
and tracer-lipids were mixed in a glass tube (12 × 75 mm) 
according to the scheme in Table 1. While   vortexing the solvent 
was evaporated under a thin   nitrogen gas stream. High-vacuum 
drying of the lipid film was   followed by hydration in 0.47 mL 
glucose (5%)   resulting in a 40 mM total lipid solution. The tubes 
were sealed and placed at 50°C for 30 minutes with repeated 
rotary   movement to ensure complete hydration of the lipids 
and left overnight at room temperature. The next day the lipo-
some preparations were sonicated for 2 minutes at 50°C and 
then downsized using a small-scale extruder (Avanti Polar) as 
above.   Sonication for 5 minutes with this preparation caused 
clearing of the solution indicative of disrupted liposomes, hence 
the time was reduced to 2 minutes. MALDI-TOF mass spec-
trometry analysis of the liposome preparation made at 20 and 
300 µmoL scales respectively did not reveal any differences in 
the composition (TL Andresen, personal communication).
DNA/lipoplex formation, in vitro,  
and in vivo transfection
Adherent H1299 were plated the day prior to the experiment 
in 6-well plates, with 300,000 cells per well. NCI-H69 cells 
growing in suspension were single-cell resuspended on the 
day of the experiment and counted in a hemocytometer using 
Trypan Blue (0.4%) staining to discriminate from dead cells 
before placing 2 × 106 cells in 6 well plates. If the effect of 
endocytosis inhibitors was found in the   experiment, the cells 
were incubated with inhibitors for one hour prior to lipoplex 
addition. Initially, the cytotoxicity of endocytosis inhibitors: 
chloroquine (inhibiting   acidification of   endosomes and lyso-
some fusion),27 chlorpromazine (  inhibiting   clathrin-mediated 
endocytosis),28 filipin (  inhibiting   caveaolae-mediated endo-
cytosis),29,30 and cytochalasin B (inhibiting macropinocyto-
sis)31 was determined in NCI-H69 and H1299 cells in the 
range reported previously by others. Concentrations causing 
approximately 30% decrease in MTT cell viability32 were 
selected (data not shown, see   legend of Figure 6). Twenty 
microlitres (0.8 µmoL) of   liposome preparations with vary-
ing amounts of PEG-lipid were diluted and mixed by rapid 
pipetting up and down with DNA   solutions containing 
pEGFP-N1 and pCMV-LUC (22.5 µg each) yielding a total 
volume of 100 µL DNA/lipoplex solution.7 For in vitro studies, 
after 30 minutes at RT the DNA/lipoplex (2.25 µg/40 nmoL) 
was added to cells in full growth medium and incubated for 2 
days at 37°C before analysis of reporter activity. For in vivo 
applications the mixing was done with maximally 300 µL of 
total volume, and batches were pooled if larger amounts were 
required. Intravenous injection of 100 µL was administered 
within 2 hours of mixing.
Gene expression analysis
Adherent cells were trypsinized and suspension cells were 
  single-cell resuspended and transferred to Eppendorf tubes 
in two aliquots and washed with phosphate-buffered saline 
(PBS). One aliquot was analyzed by flow cytometry using a 
FACS Canto II instrument (BD Biosciences, Franklin Lakes, 
NJ, USA) gating EGFP-positive cells using the blue laser 
(488 nm) and detecting fluorescence light in each cell at 
538 ± 10 nm. A nontransfected control cell sample was used 
to adjust for autofluorescence. The second cell aliquot of each 
sample was pelleted and lysed in 100 µL passive lysis buffer 
(Promega Inc., Madison, WI, USA) for 10   minutes. After 
centrifugation for 1 minute, the supernatant was analyzed 
for luciferase activity (20 µL; Luciferase kit, Promega) using 
a luminometer (Lumat LB9507; Berthold, Bad Wildbad, 
Germany) and total protein concentration (20 µL, 10 times 
diluted, BCA kit, Pierce/Thermo, Rockford, IL, USA) using 
an OpsysMR microplate reader (Dynex Technologies GmbH, 
Berlin, Germany). Using a   purified, recombinant firefly 
luciferase (Promega) for   standardization, luciferase activity 
was expressed as picogram luciferase enzyme per   milligram 
of total protein (pg luc/mg   protein). When   fluorescing lipid 
was incorporated in the   lipoplex, the cell lysates of   transfected 
cell samples were analyzed in a microplate fluorometer (Ex. 
485 ± 10 nm, Em. 530 ± 10 nm, Synergy 2, Biotek Instru-
ments Inc., Winooski, VT, USA).
Particle characterization
DNA/lipoplexes were analyzed by agarose gel (1%) 
  electrophoresis followed by ethidium bromide staining to 
Table 1 Liposome components
Name Lipid components (moL%)
DOTAP Chol DSPE- 
PEG2k
25-NBD- 
chol
3H-CHE
A-0 50 50 (48.5) 0 (1.5) 0.0025
B-2 50 48 (46.5) 2 (1.5) 0.0025
C-4 50 46 (44.5) 4 (1.5) 0.0025
D-10 50 40 (38.5) 10 (1.5) 0.0025
Notes: The names of the formulations used in the study reflect the percentage 
of  PEG-lipid.  When  fluorescent  cholesterol  was  included,  1.5  mol%  25-NBD-
cholesterol  was  added  and  the  unlabeled  cholesterol  was  reduced  accordingly 
(shown  in  parentheses).  For  assessment  of  biodistribution  in  vivo  3H-CHE  was 
included (0.0025 mol%, 50 Ci/mmoL).
Abbreviations: DOTAP/chol, 1,2-dioleoyl-3-trimethylammonium-propane (chloride 
salt)/cholesterol; PEG, polyethylene glycol; NBD, 7-nitro-2-1,3-benzoxadiazol; SCLC, 
small cell lung carcinoma; NSCLC, non-small cell lung carcinoma; i.v., intravenous; 
PDI, polydispersity index.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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visualize bound and free plasmid DNA. A Zetasizer Nano 
ZS (Malvern Instruments Inc., Malvern, UK) was used for 
  characterizing the particle size by dynamic light scattering 
and zeta potential. Preparations of liposomes and DNA/lipo-
plexes were diluted to approximately 1 mM total lipid and 
placed in a clear disposable zeta cell (Malvern). First, size was 
determined using four cycles of 3 minutes at standard settings 
for vesicles and with general purpose parameter settings. The 
quality of size measurements given as the volume-weighted 
mean diameter were analyzed by   evaluating polydispersity 
index (PDI), scattering correlation, and cumulants fit. Subse-
quently samples were analyzed for zeta potential of particles 
using standard settings with three repeated measurements of 
.20 zeta runs and assessing the quality of measurements by 
evaluation of the phase plot.
SCLC tumor model establishment
The SCLC xenograft model was established by the injec-
tion of 5 × 106 NCI-H69 cells per flank subcutaneously into 
6–8-week-old male nude NMRI mice.16 Tumors from injected 
mice (termed passage 0) were used for serial transplantation 
of mice that entered experimental protocols (passage 1) or 
used for serial transplantation of new animals (passage 2). 
Xenograft tumors used in the experiments were passaged 
up to four times. Untreated tumors from each passage were 
subjected to pathological analysis to evaluate the existence 
of clinically validated SCLC markers.
Luciferase activity, pharmacokinetics,  
biodistribution in vivo
Male NMRI nude mice were injected in the lateral tail vein 
with 100 µL lipoplex prepared as described above.   Unlabeled 
lipoplex without PEG-lipid (A-0*) was administered once 
daily for three consecutive days and on the fourth day 
animals were euthanized by cervical dislocation and organ 
samples (tumor, heart, lung, liver, kidney, spleen, and tail 
(1 cm upward of injection site); 50–150 mg) were isolated 
and snap frozen. Organ samples were mixed with 1 mL 
  passive lysis buffer (Promega Inc.) supplemented with Pro-
tease Inhibitor Cocktail Set III (Merck Chemicals, Glostrup, 
Denmark) grinded in a ball mill (Qiagen) using one steel ball 
(5 mm) and shaking for 6 minutes. After   centrifugation for 
10 minutes at 4°C the supernatant was isolated and luciferase 
activity and protein concentration was measured as described 
previously.
Using the lipid marker 3H-CHE,13,33 tritium-labeled DNA/
lipoplexes with varying degrees of PEGylation were injected 
in a single dose (100 µL) containing   approximately 1 µCi 
tritium label. In these experiments half of the   homogenate 
(500 µL) was isolated for scintillation counting before 
  centrifugation. If more than 90% of the counts were found in 
the tail sample the injection was considered as failed and the 
mouse was excluded from the experiment. Blood samples 
(100 µL) were drawn from the eye by periobital plexus 
  puncture after 15 minutes, 2 hours, 5 hours, and 24 hours, 
and immediately mixed with 10 mL scintillation liquid 
(  UltimaGold, Perkin Elmer, Skovlunde, Denmark) and 
counted in a Beckman LS 6500 liquid scintillation counter 
(Beckman Instruments, Fullerton, CA, USA). After the last 
blood sampling the animals were euthanized and organs 
sampled and analyzed as above. Due to the low systemic 
distribution of radiolabel no blood correction factor was 
applied to organ values.34
Results
Gene expression analysis in vivo
The DOTAP/chol/DNA lipoplex has previously been shown 
to facilitate gene expression in primarily lung and heart 
tissue when administered intravenously by tail vein injec-
tion to NSCLC models in nude mice.6,9,35,36 We inoculated 
NCI-H69 cells subcutaneously (s.c.) on the flanks of NMRI 
nude mice for testing of the ability of the DOTAP/chol 
lipoplexes to facilitate gene expression in SCLC s.c. xeno-
grafts. The tumors reached approximately 200–500 mm3 in 
size when the experiment was started. Lipoplexes were pre-
pared with DOTAP/chol (formulation A-0*) and pCMV-LUC 
plasmid and three daily tail vein injections of xenografted 
nude mice were performed. The animals were sacrificed 
on the fourth day and selected organs were sampled and 
luciferase   activity was assayed in protein extracts (Figure 1). 
We detected luciferase expression in lung and heart tissue, 
whereas the activity was three to four orders of magnitude 
100000
10000
1000
100
10
1
Tumor
p
g
 
l
u
c
 
e
n
z
y
m
e
/
g
 
p
r
o
t
e
i
n
Heart LungL iver Kidney Spleen
Figure  1  Luciferase  reporter  gene  expression  in  vivo.  After  three  consecutive 
daily tail vein injections of DOTAP/chol/DNA lipoplex (A-0*) in nude mice organs 
were sampled on the fourth day and assayed for luciferase activity, n = 4. Assay 
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lower, below assay background (10 pg luc per g protein) in 
tumor, liver, kidney, and spleen tissue samples. We inter-
preted this finding as showing that DOTAP/chol lipoplexes 
have insufficient systemic stability to reach beyond first-
pass organs and speculated that the required improvement 
in   biodistribution might be obtained by adding a PEGylated 
lipid to the lipoplex formulation.
Liposome particle and lipoplex 
characterization
In order to investigate the usability of modifying the lipoplex 
with PEG-polymer, four formulations of 100 nm-extruded 
DOTAP/chol liposomes designated A-0, B-2, C-4, and 
D-10, containing 0%, 2%, 4%, or 10% DSPE-PEG2000 lipid 
respectively, were evaluated. Table 1 shows the composition 
of each formulation. Immediately after mixing the liposomes 
with plasmid DNA the solution became cloudy white indicat-
ing lipoplex formation, as observed by others.5,7
A small aliquot of lipoplex (0.2% of each preparation) 
was analyzed by agarose gel electrophoresis.37 In agreement 
with predicted molar excess of lipid, all DNA was complexed 
to lipoplex, since no DNA was observed migrating as free 
plasmid DNA (Figure 2).
The ratio of positively charged lipids to negatively 
charged DNA was calculated to be 2.6.9 Before and after 
mixing with DNA the size, polydispersity index (PDI), and 
charge were assessed using dynamic light scattering and zeta 
potential measurements (a typical experiment is described 
in Figure 3).
All four liposome preparations have particle sizes in the 
range 113 ± 0.5–130 ± 0.4 nm and low polydispersity indices 
(0.066 ± 0.012–0.149 ± 0.01). The zeta potential is gradually 
decreasing from +65.6 ± 0.74 mV in A-0 to +44.7 ± 3.47 mV 
in D-10 concurrent with increasing content of the negatively 
charged DSPE-PEG2000 lipid. The model of PEG-surface 
structure being mushroom-like at concentrations below 
4%, whereas brush-like structures exist at higher PEG-lipid 
mol-percentages (eg, 10%).23,24 Interestingly, we found that 
upon mixing with DNA the size of lipoplexes increase and 
lipoplexes containing 2% or 4% PEG-lipid form micrometer 
scale aggregates, whereas the A-0 and D-10 lipoplex have 
sizes 784 ± 49 and 327 ± 5.3 nm, respectively. This finding 
is in accordance with PDI values that are close to 1 for A-0, 
B-2, and C-4 lipoplexes indicating high turbidity, whereas 
D-10 lipoplex has a medium PDI of 0.472. Upon mixing with 
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Figure 2 Agarose gel electrophoresis/ethidium bromide staining of DNA/lipoplexes 
with different content of PEG-lipid compared to the migration of free plasmid DNA 
(free DNA) and a DNA size marker.
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negatively charged DNA, the zeta potential of the particles 
is reduced accordingly, but the lipoplex particles/aggregates 
maintain a high positive charge (ranging from 47.8 ± 1.56 to 
35.4 ± 1.58). The properties of lipoplexes described above were 
consistently found when lipids were prepared at the scale of 
20 µmoL in at least three independent experiments, however 
when preparing the DOTAP/chol particles according to the 
standard protocol7 at the scale of 300 µmoL (designated A-0* 
in Figure 3) the lipoplexes were measured to be below half 
a micrometer (492 ± 21 nm) in accordance with previously 
  published results of lipoplexes used for translation investiga-
tions.9 Zeta-potential measurements were similar for lipoplexes 
arranged at both preparation scales (A-0 and A-0*).
Gene expression analysis in vitro
Equal amounts of pCMV-LUC- and pEGFP-N1-expression 
plasmids encoding LUC and EGFP genes were mixed with 
A-0, B-2, C-4, or D-10 liposomes and used in transfection 
of two lung cancer cell lines H1299 or NCI-H69. Forty-eight 
hours later the cells were analyzed for reporter gene expres-
sion, either by measuring the percentage of EGFP-positive 
cells by flow cytometry (Figure 4a) or by measuring the 
overall amount of luciferase activity expressed in relation 
to total protein in cell lysates (Figure 4b).
With the presence of PEG-lipid in the lipoplex a dra-
matic decrease in the number of EGFP-positive cells from 
47% ± 6.9% with A-0 to 3.6% ± 1.8% with B-2 in H1299 
cells and from 30% ± 1.9% with A-0 to 2.6% ± 1.8% with B-2 
in NCI-H69 cells. Transfections with lipoplexes C-4 or D-10 
yielded even lower transfection efficiencies around 1% to 2% 
of the cells being successfully transfected (Figure 4a). In accor-
dance with this, the luciferase activity is gradually decreasing 
roughly 10-fold in each step from 213 ± 89 ng luc/mg protein 
with A-0 to 145 ± 47 pg luc/mg protein with D-10 in H1299 
cells and 11 ± 5.2 ng luc/mg protein with A-0 to 3.0 ± 1.2 pg 
luc/mg protein with D-10 in NCI-H69 when analyzing the 
cell samples transfected with lipoplexes A-0, B-2, C-4, and 
D-10, respectively (Figure 4b).
Kinetics of cellular uptake
In order to investigate the kinetics of cellular uptake of the 
lipoplexes the four formulations with increasing PEG-lipid 
were prepared with 1.5% 25-NBD-cholesterol, a green 
  fluorescing lipid reporter that has previously been used 
to study liposome transport.38,39 Since the EGFP expres-
sion would overlap spectrally with the labeled cholesterol 
  fluorescence, only LUC-expression plasmid was used for 
lipoplex formation. Essentially the same reporter activities 
were obtained as with the unlabeled lipoplexes (data not 
shown). Furthermore, microscopic and FACS flow   cytometry 
analyses showed that for all four mol-percentages of PEG-
lipid, virtually all cells (99%) contained the fluorescing 
  cholesterol in similar subcellular compartments two days 
after transfection (Figure 5a) and this prompted us to measure 
the uptake kinetics on a shorter time scale.
Hence Figure 5b shows the cell lysate fluorescence of 
NBD-cholesterol at 1, 4, 24, and 48 hours after addition 
of labeled lipoplexes to H1299 cells. A   remarkable differ-
ence in uptake kinetics is observed. The fluorescence in 
cells transfected with lipoplex without PEG-lipid (A-0) is 
unchanged from one hour after   transfection to two days 
(ANOVA: P = 0.45: no change), whereas   fluorescence in 
cells transfected with lipoplexes with 2%, 4%, or 10% PEG-
lipid (B-2, C-4, or D-10) accumulates over time (ANOVA: 
P values , 0.002 in all three cases: significant change), 
reaching a maximum of fluorescence after 24 to 48 hours. 
Regression analysis confirms this difference (linear equation 
fits are shown in Figure 5 legend).
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Mechanism of cellular uptake, effect  
of endocytosis inhibitors
In order to investigate whether the changed transfectability of 
PEGylated lipoplexes could be due to an altered uptake mech-
anism cell culture transfections were done in the presence 
of four different drugs known to interfere with endocytosis, 
namely chloroquine that inhibits acidification of endosomes 
and lysosome fusion,27 chlorpromazine that inhibit clathrin-
mediated endocytosis,28 filipin, a sterol binding compound 
that inhibit caveaolae-mediated endocytosis29 and cytochalasin 
B that inhibit actin polymerization and macropinocytosis,31 
all of which have been described as being useful in relation 
to nonviral gene transfer.40 Luciferase reporter activity was 
evaluated in H1299 and NCI-H69 cells and most profound 
effects were observed in NCI-H69 cells (Figure 6a).
Here it was found that all lipoplexes were sensitive to 
cytochalasin B decreasing luciferase activity between 4- and 
16-fold (22–24-fold) indicating that the uptake mechanism 
involves macropinocytosis or that actin   filaments are involved 
in intracellular processing. Only the transfection with the larg-
est particles made with DNA/C-4 lipoplexes was decreased 
two fold by filipin indicative of a   caveolae-dependent uptake. 
With regards to chloroquine and chlorpromazine a large dif-
ference in sensitivity was observed between non-PEGylated 
and PEGylated lipoplexes. A-0-based   lipoplexes yielded 
roughly 16-fold less reporter activity in the   presence of 
these inhibitors, and in contrast hereto, PEGylated   lipoplexes 
made with C-4 yielded four fold more reporter activity, and 
D-10-based lipoplexes facilitated 1.6-fold more luciferase 
activity in the presence of chloroquine. In adherent H1299 
cells (Figure 6b), effects of inhibitors were less significant, 
although the same pattern of lipoplex sensitivity could be rec-
ognized from that of NCI-H69 cells. Chloroquine and chlo-
rpromazine reduced luciferase   activity 16- and 32-fold, 
respectively in case of A-0 lipoplex, whereas B-2 lipoplexes 
yielded 16-fold more activity when the cells were exposed 
to chlorpromazine. Although the exact action of inhibitors 
may be uncertain, taken together these data strongly suggest 
that the cellular uptake of naked and PEGylated lipoplexes 
depend on different mechanisms. All   experiments were 
averaged from 3–5 independent experiments and at least two 
different preparations of liposomes.
Biodistribution and stability
Discrepancies between transfection in vitro and in vivo has 
been reported previously41 and the finding that PEGylated 
DOTAP/chol lipoplexes are taken up efficiently over time 
by cancer cells in vitro, albeit gene expression is hampered, 
prompted us to investigate the potential of the lipoplexes for-
mulated with different moL-percentage of PEG-lipid in vivo. 
The intracellular processing of lipoplexes is   different in   various 
organs and cell types,40 and the   putative   stabilizing effect of 
PEG-lipid in the formulation could influence the effective-
ness in cellular transfection between the four   formulations 
in vivo. Using the nonexchangeable and nonmetabolizeable 
lipid marker 3H-CHE,33 lipoplexes were prepared and injected 
in the tail vein of tumor-bearing NMRI nude mice and blood 
was drawn by periobital plexus sampling 15 minutes, 2 hours, 
5 hours, and 24 hours after injection of lipoplex.
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The radioactive dose was 0.5 µCi corresponding to approxi-
mately 1.2 × 107 cpm (background 9 cpm). Interestingly, when 
100 µL blood samples from animals were counted by scintil-
lation, only small amounts of tritium were found, indicating 
a poor systemic spreading of the radioactive dose to the vein 
blood drawn from the eye. Figure 7a shows the tritium counts of 
isolated blood samples over time after background subtraction. 
Blood sampled 15 minutes after tail vein injection of lipoplexes 
with 0%, 2%, or 4% PEG-lipid contained tritium only 6 to 
9 times over background, whereas samples drawn from animals 
injected with D-10 lipoplex contained approximately 18 times 
over background, however in all cases, only a very small fraction 
of the injected dose. Five hours after injection all blood samples 
contained the same low amount of radioactivity.
After 24 hours the animals were sacrificed and selected 
organs were sampled and assayed for luciferase activity and 
accumulation of tritium-tracer. Figure 7b shows the luciferase 
activity in tumor, heart, lung, liver, kidney, and spleen samples 
from animals injected with a single dose of lipoplex formu-
lated with 0%, 2%, 4%, or 10% PEG-lipid. In general, only 
heart and lung tissue of animals   receiving plasmid DNA in 
lipoplexes contain luciferase activity   considerably above assay 
background, and this was gradually decreasing with increasing 
PEGylation. D-10 lipoplexes yielded more luciferase activity 
in the lung than C-4, however no activity in heart tissue could 
be measured. Additionally, the spleen sample from mice 
injected with A-0 lipoplex showed luciferase activity above 
background. Importantly, no luciferase activity was measured 
in tumor tissue from mice injected with lipoplex.
The relative distribution of radioactive lipid tracer 
in tumor, heart, lung, liver, kidney, and spleen tissues is 
shown in Figure 7c and there is a gradual change with high 
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  accumulation in the heart and lungs in case of lipoplex A-0, 
B-2, and C-4 to high liver accumulation of the lipoplex 
containing 10% PEG-lipid (D-10).
Discussion
Effect of PEGylation in vitro
Previous efforts in nonviral gene delivery using DOTAP/
chol-based lipoplexes have proven successful in   obtaining 
efficient cellular transfection in vitro and in vivo using 
  xenograft subcutaneous flank tumors by intratumoral   injection 
or   orthotopic micrometastatic lung tumor model of NSCLC by 
intravenous injection.6 We recently reported the successful use 
of DOTAP/chol lipoplexes for delivery of suicide gene therapy 
by intratumoral injection.16 The rapid clearance from the   system 
of intravenously injected DOTAP/chol-based lipoplexes have 
been reported,13,42 and since our gene therapy strategy is aimed 
at the systemic treatment of subcutaneous xenograft tumors14 
and eventually disseminated SCLC, in this study we sought 
to stabilize and increase the circulation time of DOTAP/
chol-based lipoplexes that have been modified with different 
amounts of PEG-lipid, ie, without abolishing the eminent 
  ability to transfect cells.43,44 Several other works have reported 
the effect of PEGylation of lipoplexes made from DOTAP or 
other cationic lipid and with DOPE as the helper lipid,25,26,45–47 
and we discuss these in relation to our findings with PEGylation 
of DOTAP/chol-based lipoplexes further below.
A remarkable threshold in physical properties appears to 
exist at 5% PEG-lipid in lipoplexes. PEG-lipid content of a 
few to 4% causes aggregation and micrometer-sized particles 
whereas 5% to 10% of PEGylated particles remain smaller. 
We applied the lipoplex conditions of Ramesh7 which utilize 
a P/N ratio of 2.6, whereas others have used less DNA.25,48 
Our findings are in alignment with the recently reported result 
of   Mignet et al26 who tested several percentages of DSPE-
PEG2000 in lipoplexes and found that large aggregates occur in 
case of 1.25% and 2.5%, but not 5% PEG-lipid in the   formula. 
Similarly, a size stabilizing effect exist when more than 4–5 
moL% of a mono-alkyl- or cholesteryl-anchored PEG-lipid is 
incorporated into lipoplexes at neutral charge ratio.47
The biophysical basis of this difference may rely on the 
surface density of PEG-lipid that in less than 5% allow for 
a mushroom-structured PEG-lipids where PEG-polymers do 
not interact.23,24 However, upon lipoplexing where negatively 
charged DNA is added, PEG-lipids may interdigit with PEG 
of other particles and hence favor aggregation.
Since 5% to 10% PEG on liposome surface forms   brush-like 
structure it seems an attractive model that   mushroom-structured 
PEG on the cationic liposome surface will lead to aggregated 
lipoplexes and brush like-structured PEG lead to more stable 
structures. It may be speculated that all PEG-lipid is not 
present in the lipoplex surface or even that some may form 
micelles, since the effect of   polymer-based micelle formation 
has been reported when attempting to incorporate high mol% 
of DSPE-PEG2000 in liposome formulation.49 However, in 
this   theoretical study it was predicted that 10% PEG2000-lipid 
would incorporate into liposome membrane spontaneously, 
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whereas longer PEG-chains might form micellar structures. The 
effect of inserting saturated lipid-PEG components in saturated 
membranes has been studied by spin-label electron spin reso-
nance (ESR) spectroscopy.50 To our knowledge it has not been 
shown to what extent saturated PEG-lipids (DSPE-PEG2000) 
form micelles or pack into an unsaturated DOTAP/“bulky” 
lipid (cholesterol) membrane, but the   aforementioned studies 
render it likely that although some PEG-lipid may be buried 
into the lamellar lipoplex structure, all PEG-lipid is retained 
in the lipoplex. Furthermore, the fact that the zeta potential of 
DOTAP/chol/DSPE-PEG2000 liposomes with 10% PEG-lipid 
is lower than 4% PEG-lipid (Figure 3, white columns), presum-
ably due to the negative charge in the PE-head group, support 
that liposome composition is in accordance with the expected 
from the formulation.
When analyzing lipoplexes in vitro we found an inverse 
correlation between the amount of PEG-lipid in the lipoplex 
and reporter gene activity in both easy-to-transfect, adherent 
lung cancer H1299 cells and hard-to-transfect, suspension lung 
cancer NCI-H69 cells. Luciferase activity measurements showed 
that each stepwise increase in PEG-lipid percentage roughly 
reduced the luciferase activity by 10-fold, or three orders of 
magnitude. In accordance, the percentage of EGFP expressing 
cells was reduced one to two orders of magnitude to a level just 
above the detection limit. Using DOPE as the helper lipid several 
researchers have demonstrated a   similar negative influence of 
increasing PEG-lipid in lipoplex formulation.45,46 Nicolazzi et al 
studied PEGylated lipoplexes with various charged peptide 
linkers in the PEG-lipid and confirmed the negative influence 
on transfection efficiency when analyzing lipoplexes with 5% 
PEG-lipid.25 Intriguingly, a post insertion method for PEGylation 
of formed lipoplexes was used that enabled particles of much 
lower positive charge between 5 and 20 mV compared to 35 to 
40 mV for PEGylated lipoplexes in this study, where PEG-lipid 
was incorporated from the beginning.
It could be speculated that lipoplex uptake mechanism and 
intracellular release could be altered by   PEGylation, since it has 
been suggested that DOTAP/chol-based   lipoplexes enter the 
cell by direct plasma membrane fusion5 or   endocytosis-based 
upon electrostatic interactions.40,51,52 Using a NBD-cholesterol 
derivate we labeled the lipoplexes so that the lipid uptake could 
be monitored fluorometrically and it became evident that the 
kinetics of cellular uptake differs between PEGylated and non-
PEGylated lipoplexes. Using a cell lysate microplate assay it was 
observed that within the first hour after addition, non-PEGylated 
lipoplexes enter the cells to a saturating limit. In contrast the 
uptake of PEGylated lipoplexes is gradually increasing over 
time and supposedly depends on an endocytotic mechanism 
that allow the accumulation of higher amounts of fluorescently 
labeled lipoplex – at least in the case of lipoplexes with 10% 
PEG-lipid where the fluorescent signal is twice that obtained 
from cells transfected with non-PEGylated lipoplexes.
This finding was further supported when radiolabeled 
lipoplexes were tested in cell culture and the label accumu-
lating in cells after two days was measured (data not shown). 
Interestingly, fluorescence microscopy and flow cytometry 
show that with all four formulations virtually all cells contain 
the NBD-label after two days, hence it is indicated that the lost 
ability of PEGylated lipoplex to successfully transfect cells 
and allow the expression of reporter gene is due to   defective 
intracellular processing and endocytic release of plasmid DNA. 
In support of this hypothesis we noted that lipoplexes made 
with plasmid and DODAC/DOPE/DSPE-PEG2000 showed 
that increasing mol% of PEG-lipid reduced the   transfection 
after 24 hours.46 However, when   analyzing cellular uptake of 
lipoplexes with radioactive lipids or nucleic acids it was con-
cluded that PEG-induced inhibition of   transfection did not cor-
relate with a reduction in   endocytosis. In addition, the uptake 
of   oligodeoxynucleotides (ODN) complexed in DODAC/
DOPE/PEG2000-ceramide (5%) lipoplexes was investigated 
and it was found that the stronger uptake correlated with longer 
ceramide PEG-anchors.45   Furthermore, using confocal micros-
copy an inverse   correlation between ceramide lipid length and 
  successful nuclear transfer of fluorescently labeled ODN was 
  suggested, supporting the notion that DSPE-PEG2000 being 
C-18-anchored would inhibit endosomal escape similarly in 
our experiments and that unsuccessful transgene expression 
from PEGylated lipoplexes relate to that.
A profound change in sensitivity between non-  PEGylated 
and PEGylated lipoplexes towards four endocytosis   inhibitors 
thought to interfere with different uptake pathways was 
observed. Although the inhibitors may exert nonspecific 
effects,53 apparently, clathrin-coated endosomes are engaged 
in transfection using naked lipoplexes, since chlorpromazine 
reduced luciferase activity 8–16-fold in the lung cancer cell 
lines in our study and this was also found by others.54 The 
increase in luciferase activity from PEGylated lipoplexes when 
cells were exposed to chlorpromazine could be a   competition 
effect of endocytic pathways – one being   inhibited and thereby 
favoring another. Similarly, the   sensitivity of A-0 lipoplexes 
towards chloroquine was also observed in both cell lines and 
in contrast chloroquine seems to have a stimulating effect 
on reporter activity from   PEGylated lipoplexes. The latter is 
in alignment with the notion that PEGylated lipo-particles 
need to unload the DNA cargo before endosome fusion to 
lysosomes and degradation,55 however the inhibiting effect of International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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chloroquine on   transfection with A-0-based lipoplexes was not 
easily interpretable. Several researchers have demonstrated 
that gene expression is increased in the presence of chloro-
quine when using 4% to 10% PEGylated small unilaminary 
liposomes as delivery vehicle involving passively targeted27 
or receptor-targeted28 endocytosis. At least in NCI-H69 cells 
the   sensitivity towards cytochalasin B was significant with all 
  lipoplex   formulations and hence a   macropinocytosis-dependent 
uptake   mechanism is suggested,56 although it cannot be   formally 
ruled out that the disruption of endosomal trafficking by 
actin   de-polymerization will influence the uptake through an 
unknown mechanism.31
Difference in inhibitor sensitivity may depend on cell size 
and growth properties, NCI-H69 being small,   growing in sus-
pension, and adherent H1299 that are large and   flattened out may 
require longer preincubation time, hence the   cellular uptake of 
cationic lipoplexes57 and PEGylated lipoparticles may be cell 
type dependent in relation to endocytotic   pathways at work.58
Effect of PEGylation in vivo
The fate of the radiolabel allowed us to assess the systemic 
availability and retention in various organs. Surprisingly 
little radioactivity was detectable in blood isolated from the 
eye, only 0.01% to 0.1% of the injected dose was isolated in 
100 µL blood 15 minutes after injection. A mouse weighing 
30 g is estimated to contain approximately 3 g blood59 and 
hence if the entire dose was freely distributed in the blood and 
available we would expect 3.3%. One possibility is that due 
to the high positive charge (. +40 mV) and large   aggregate 
size of the lipoplexes (all .300 nm) they do not make a 
full systemic passage, but are retained in the first primary 
organs after intravenous injection. In the heart and lungs 
all lipoplexes with 0% to 10% PEG-lipid are successful in 
transfection, but gradually decreasing corresponding to the 
activities measured in vitro. Comparing the reporter activity 
measured from lipoplexes made with A-0* in Figure 1 and A-0 
in Figure 7b, there is no difference (t-test, P value = 0.35), 
although the first was applied in three daily injections and the 
latter only once. We speculate that the duration of expression 
may not be long or that one dose is saturating in the reachable 
sites with this intravenous delivery method. Furthermore it 
is suggested that A-0 lipoplexes being 700 nm in size are as 
efficient in heart/lung transfection as A-0* lipoplexes.
The positive charge of lipoplexes led to interaction with 
albumin and other serum proteins when exposed to serum 
or injected intravenously.48,60 Binding of lipoplexes to serum 
lipoproteins or complement factor C3 showed that it may 
have strong influence on particle size, DNA integrity, and 
transfection ability.60–62 When lipoplex size was assessed 
in the presence of serum proteins it was found that 5% 
  PEG-lipid prevented a large increase in size over several 
hours that was observed in the case of non-PEGylated lipo-
plexes. The difference to the lipoplexes of the present study is 
that the N/P ratio is lower (1/5, less DNA complexed) and our 
particle’s surface charge is much higher presumably due to 
preincorporation of PEG-lipid that may not shield the charge 
as effectively as in case of postincorporation. Hence it may 
be amenable to utilize a lower N/P ratio, eg, 1/4 as reported, 
however that cause a decreased transfection in vivo.48
Opsonization and uptake by phagocytic cells of the 
reticuloendothelial system (RES) present in blood was 
therefore expected in case of all four lipoplexes and indeed 
approximately 20% of the label resides in the spleen, since 
phagocytic blood cells accumulate later in the spleen as it was 
reported for liposome particles previously.20,63   Furthermore, 
luciferase activity found in the spleen when using A-0 
  lipoplexes could indicate successful transfection of RES 
cells accumulating in this organ (Figure 7b).
Analysis of lipoplexes with 0%, 2%, 4%, and 10% 
PEG-lipid allowed us to demonstrate that low PEG-lipid 
  percentage (B-2, C-4) leads to severe lipoplex   aggregation 
causing   retention in lung/heart tissue similar to naked 
  lipoplexes (A-0) that is not highly aggregated.   Interestingly, 
with D-10 lipoplexes we observed a distribution in abdomi-
nal organs that suggests that heart/lung retention is over-
come and although not being able to transfect cells in liver, 
  kidney, and spleen lipoplexes are accumulating here. A 
similar   distribution in inner organs was found when non-
transplanted mice were used (data not shown) indicating 
that the inverse relation between lung/heart accumulation 
and 10%   PEGylation is true also in noncancerous animals. 
Mice injected with lipoplexes maintained a normal behavior 
during the experiment, although we measured a significant 
weight loss of up to 10% in most of the animals. This could 
relate to some kind of pulmonary obstruction, however this 
was not visible in H&E staining of tissue sections, that were 
evaluated by a trained pathologist.
These observations support the notion that PEG shield-
ing of lipo-particles increase systemic circulation,64 however 
due to the high positive surface charge only in the case of 
D10 lipoplexes was a small increase in blood availability 
measured. It has been previously reported that lipoplexes 
with 5% PEG-lipid could increase the blood availability 
marginally, however we found no increase in tumor accu-
mulation.25,26 Neither of the lipoplex formulations convey 
delivery to tumor sites, hence our data confirm previous International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
382
Gjetting et al
reports that (non-PEGylated) DOTAP/chol lipoplexes2,13 or 
cationic DOPE-based lipoplexes including PEG-lipids25,45,48 
do not mediate delivery to xenograft subcutaneous tumors 
to any useful extend.
Conclusion
We explored the potential of improving systemic stability 
and circulation of DOTAP/chol-based lipoplexes for in vivo 
cell transfection by including a PEG-lipid in the formulation. 
Although we observed a decrease in the retention in lung and 
heart tissues the systemic circulation was not considerably 
improved and the eminent properties of providing transfec-
tion and ectopic gene expression are lost upon increasing 
degrees of PEGylation, hereby rendering it unsuitable as a 
systemic delivery method for plasmid DNA-bound genetic 
medicine for extrathoracic sites.
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